Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Nature Chemical Biology volume 14, pages 163–170 (2018)Cite this article

Subjects

Abstract

Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN). To our surprise, THAL-SNS-032 induced rapid degradation of CDK9 without affecting the levels of other SNS-032 targets. Moreover, the transcriptional changes elicited by THAL-SNS-032 were more like those caused by NVP-2 than those induced by SNS-032. Notably, compound washout did not significantly reduce levels of THAL-SNS-032-induced apoptosis, suggesting that CDK9 degradation had prolonged cytotoxic effects compared with CDK9 inhibition. Thus, our findings suggest that thalidomide conjugation represents a promising strategy for converting multi-targeted inhibitors into selective degraders and reveal that kinase degradation can induce distinct pharmacological effects compared with inhibition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: THAL-SNS-032 selectively induces degradation of CDK9.
Figure 2: NVP-2 selectively inhibits CDK9.
Figure 3: THAL-SNS-032 exhibits CRBN-dependent anti-proliferative and pro-apoptotic effects.
Figure 4: THAL-SNS-032 exhibits transcriptional effects consistent with a selective CDK9 inhibitor.
Figure 5: THAL-SNS-032 diminishes elongating polymerase II.

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15, 122 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dorée, M. & Galas, S. The cyclin-dependent protein kinases and the control of cell division. FASEB J. 8, 1114–1121 (1994).

    Article  PubMed  Google Scholar 

  3. Sun, T., Co, N.N. & Wong, N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 449, 163–168 (2014).

    Article  CAS  PubMed  Google Scholar 

  4. Liu, Y., Cheng, K., Gong, K., Fu, A.K.Y. & Ip, N.Y. Pctaire1 phosphorylates N-ethylmaleimide-sensitive fusion protein: implications in the regulation of its hexamerization and exocytosis. J. Biol. Chem. 281, 9852–9858 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. Peng, J., Marshall, N.F. & Price, D.H. Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J. Biol. Chem. 273, 13855–13860 (1998).

    Article  CAS  PubMed  Google Scholar 

  6. Hirose, Y. & Ohkuma, Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J. Biochem. 141, 601–608 (2007).

    Article  CAS  PubMed  Google Scholar 

  7. Wada, T., Takagi, T., Yamaguchi, Y., Watanabe, D. & Handa, H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 17, 7395–7403 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yamada, T. et al. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol. Cell 21, 227–237 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Gilchrist, D.A. et al. NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly. Genes Dev. 22, 1921–1933 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Huang, C.-H. et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 28, 1800–1814 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lu, H. et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. eLife 4, e06535 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Rahl, P.B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432–445 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Okuda, H., Takahashi, S., Takaori-Kondo, A. & Yokoyama, A. TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription. Cell Cycle 15, 2712–2722 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Samarakkody, A. et al. RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition. Nucleic Acids Res. 43, 3938–3949 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chao, S.-H. et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345–28348 (2000).

    Article  CAS  PubMed  Google Scholar 

  16. König, A., Schwartz, G.K., Mohammad, R.M., Al-Katib, A. & Gabrilove, J.L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90, 4307–4312 (1997).

    Article  PubMed  Google Scholar 

  17. Sedlacek, H. et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9, 1143–1168 (1996).

    CAS  PubMed  Google Scholar 

  18. Chen, R., Keating, M.J., Gandhi, V. & Plunkett, W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106, 2513–2519 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Krystof, V. & Uldrijan, S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr. Drug Targets 11, 291–302 (2010).

    Article  CAS  PubMed  Google Scholar 

  20. Misra, R.N. et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47, 1719–1728 (2004).

    Article  CAS  PubMed  Google Scholar 

  21. Winter, G.E. et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lai, A.C. et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. 55, 807–810 (2016).

    Article  CAS  PubMed  Google Scholar 

  24. Rodríguez-Molina, J.B., Tseng, S.C., Simonett, S.P., Taunton, J. & Ansari, A.Z. Engineered covalent inactivation of TFIIH-kinase reveals an elongation checkpoint and results in widespread mRNA stabilization. Mol. Cell 63, 433–444 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Poss, Z.C. et al. Identification of mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics. Cell Rep. 15, 436–450 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kanin, E.I. et al. Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. Proc. Natl. Acad. Sci. USA 104, 5812–5817 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Patricelli, M.P. et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699–710 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Winter, G.E. et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 67, 5–18 e19 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. McAlister, G.C. et al. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Anal. Chem. 84, 7469–7478 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Barsanti, P.A. et al. Pyridine and pyrzaine derivatives as protein kinase modulators. International Patent No. PCT/JP2008/073864 (WO/2011/012661) (2011).

  31. Zhang, T. et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12, 876–884 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lin, C.Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lovén, J. et al. Revisiting global gene expression analysis. Cell 151, 476–482 (2012).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Boyer, L.A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947–956 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sanda, T. et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 22, 209–221 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Mitra, P., Yang, R.M., Sutton, J., Ramsay, R.G. & Gonda, T.J. CDK9 inhibitors selectively target estrogen-receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. Oncotarget 7, 9069–9083 (2016).

    PubMed  PubMed Central  Google Scholar 

  37. Bonhoure, N. et al. Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalization. Genome Res. 24, 1157–1168 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Wade, J.T. & Struhl, K. The transition from transcriptional initiation to elongation. Curr. Opin. Genet. Dev. 18, 130–136 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Patricelli, M.P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358 (2007).

    Article  CAS  PubMed  Google Scholar 

  40. Nomanbhoy, T.K. et al. Chemoproteomic evaluation of target engagement by the cyclin-dependent kinase 4 and 6 inhibitor Palbociclib correlates with cancer cell response. Biochemistry 55, 5434–5441 (2016).

    Article  CAS  PubMed  Google Scholar 

  41. Edwards, A. & Haas, W. in Multiplexed Quantitative Proteomics for High-Throughput Comprehensive Proteome Comparisons of Human Cell Lines. Proteomics in Systems Biology: Methods and Protocols (ed. J. Reinders) 1–13 (Springer New York, New York, NY, 2016).

    Google Scholar 

  42. McAlister, G.C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150–7158 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ting, L., Rad, R., Gygi, S.P. & Haas, W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat. Methods 8, 937–940 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. R Development Core Team. (R Foundation for Statistical Computing Vienna, Austria, 2013).

  45. Ritchie, M.E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Huang, W., Sherman, B.T. & Lempicki, R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).

    Article  CAS  Google Scholar 

  48. Huang, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).

    Article  CAS  Google Scholar 

  49. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Orlando, D.A. et al. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. Cell Rep. 9, 1163–1170 (2014).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank D. Buckley, E. Wang, J. Paulk, and members of the Gray and Bradner laboratories for helpful discussions. This work was supported by the US National Institutes of Health (CA179483-03 to N.K. and N.S.G., and T32GM007753 to Z.Z.), the Koch Institute and Dana-Farber/Harvard Cancer Center Bridge Grant (N.K., N.S.G., R.A.Y., C.M.O.),

Author information

Authors and Affiliations

  1. Department of Cancer Biology, Dana–Farber Cancer Institute, Boston, Massachusetts, USA

    Calla M Olson, Baishan Jiang, Yanke Liang, Zainab M Doctor, Zinan Zhang, Tinghu Zhang, Nicholas Kwiatkowski, Eric S Fischer & Nathanael S Gray

  2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA

    Calla M Olson, Baishan Jiang, Yanke Liang, Zainab M Doctor, Zinan Zhang, Tinghu Zhang, Nicholas Kwiatkowski, Eric S Fischer & Nathanael S Gray

  3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

    Michael A Erb, James E Bradner & Georg E Winter

  4. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

    Michael A Erb, James E Bradner & Georg E Winter

  5. Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Charlestown, Massachusetts, USA

    Myriam Boukhali & Wilhelm Haas

  6. ActivX Biosciences, La Jolla, California, USA

    Jennifer L Green & Tyzoon Nomanbhoy

  7. Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA

    Richard A Young

  8. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

    Richard A Young

  9. Novartis Institutes for Biomedical Sciences (NIBR), Cambridge, Massachusetts, USA

    James E Bradner

  10. Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

    Georg E Winter

Authors
  1. Calla M Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baishan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A Erb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanke Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zainab M Doctor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zinan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tinghu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicholas Kwiatkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Myriam Boukhali
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jennifer L Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wilhelm Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tyzoon Nomanbhoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Eric S Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Richard A Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. James E Bradner
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Georg E Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Nathanael S Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

N.S.G., C.M.O., N.K. and T.Z. conceived the project. N.S.G., Y.L., B.J. and T.Z. conceived and directed chemistry effort. Chemical synthesis and small-molecule structure determination was performed by T.Z., Y.L. and Z.Z. R.A.Y., N.S.G., C.M.O., M.A.E., G.E.W. and N.K. conceived genomics effort. N.K. and C.M.O. designed and executed cellular biological experimental research with input from N.S.G. and R.A.Y. W.H. and M.B. designed and executed the proteomics efforts. E.S.F. designed and executed statistical analysis of proteomics. T.N. and J.G. designed and executed the Kinativ efforts. M.A.E. designed and performed genomics data analyses. C.M.O., N.K. and N.S.G. wrote the manuscript. All of the authors edited the manuscript.

Corresponding author

Correspondence to Nathanael S Gray.

Ethics declarations

Competing interests

N.S.G. is a Scientific Founder and member of the Scientific Advisory Board of C4 Therapeutics, Syros Pharmaceuticals and Petra Pharmaceuticals and is the inventor on intellectual property licensed to these entities. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche) and C4 Therapeutics and is the inventor on intellectual property licensed to these entities. J.E.B. is now an executive and shareholder in Novartis AG. R.A.Y. is a Scientific Founder of Syros Pharmaceuticals and Marauder Therapeutics.

Supplementary information

Supplementary Text and Figures

Supplementary Results, Supplementary Tables 1–2, Supplementary Figures 1–9 (PDF 2413 kb)

Life Sciences Reporting Summary (PDF 158 kb)

Supplementary Note 1

Chemical Synthesis of THAL-SNS-032, NVP-2, THAL-NVP-2-02-099, THAL-NVP-2- 3 03-069, HAL-NVP-2-03-099, THAL-NVP-2-03-084, THAL-NVP-2-03-105. (PDF 668 kb)

Supplementary Dataset 1

Lysate Kinativ of SNS-032, THAL-SNS-032, and NVP-2 (XLSX 39 kb)

Supplementary Dataset 2

Proteomics of THAL-SNS-032 treatment (XLSX 328 kb)

Supplementary Dataset 3

Selectivity of NVP-2 by Ambit profiling (XLSX 23 kb)

Supplementary Dataset 4

Live cell Kinativ of SNS-032 and THAL-SNS-032 (XLSX 25 kb)

Supplementary Dataset 5

Live cell Kinativ of NVP-2 (XLSX 29 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olson, C., Jiang, B., Erb, M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 14, 163–170 (2018). https://doi.org/10.1038/nchembio.2538

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.2538

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research